Sphingomyelin-degrading pathways in human cells: Role in cell signalling

Chemistry and Physics of Lipids

Volumn 102, Issue 1-2, 1999, Pages 167-178

  Levade, Thierry ^a   Andrieu Abadie, Nathalie ^a   Ségui, Bruno ^a   Augé, Nathalie ^a   Chatelut, Martine ^a   Jaffrézou, Jean Pierre ^b   Salvayre, Robert ^a  

^a INSERM   (France)

^b INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Ceramide; Lysosome; Niemann Pick disease; Signalling; Sphingomyelin; Sphingomyelinase

Indexed keywords

CERAMIDE; SPHINGOLIPID; SPHINGOMYELIN; SPHINGOMYELIN PHOSPHODIESTERASE;

ENZYME ACTIVATION; HUMAN; HYDROLYSIS; LYSOSOME; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 0032869857     PISSN: 00093084     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-3084(99)00085-7     Document Type: Article

References (91)

1. Agmon V., Dinur T., Cherbu S., Dagan A., Gatt S. Administration of pyrene lipids by receptor-mediated endocytosis and their degradation in skin fibroblasts. Exp. Cell Res. 196:1991;151-157.
2. Albi E., Viola Magni M.P. Chromatin neutral sphingomyelinase and its role in hepatic regeneration. Biochem. Biophys. Res. Commun. 236:1997;29-33.
3. Alessenko A., Chatterjee S. Neutral sphingomyelinase: localization in rat liver nuclei and involvement in regeneration/proliferation. Mol. Cell. Biochem. 143:1995;169-174.
4. Andrieu N., Salvayre R., Levade T. Evidence against involvement of the acid lysosomal sphingomyelinase in the tumour-necrosis-factor- and interleukin-1-induced sphingomyelin cycle and cell proliferation in human fibroblasts. Biochem. J. 303:1994;341-345.
5. Andrieu N., Salvayre R., Jaffrézou J.P., Levade T. Low temperatures and hypertonicity do not block cytokine-induced stimulation of the sphingomyelin pathway but inhibit nuclear factor-κB activation. J. Biol. Chem. 270:1995;24518-24524.
6. Andrieu N., Salvayre R., Levade T. Comparative study of the metabolic pools of sphingomyelin and phosphatidylcholine sensitive to tumor necrosis factor. Eur. J. Biochem. 236:1996;738-745.
7. Andrieu-Abadie N., Salvayre R., Levade T. The tumor necrosis factor-sensitive pool of sphingomyelin is resynthesized in a distinct compartment of the plasma membrane. Biochem. J. 333:1998;91-97.
8. Augé N., Andrieu N., Nègre-Salvayre A., Thiers J.C., Levade T., Salvayre R. The sphingomyelin-ceramide signaling pathway is involved in oxidized low density lipoprotein-induced cell proliferation. J. Biol. Chem. 271:1996;19251-19255.
9. Augé N., Escargueil-Blanc I., Lajoie-Mazenc I. et al. Potential role for ceramide in mitogen-activated protein kinase activation and proliferation of vascular smooth muscle cells induced by oxidized low density lipoprotein. J. Biol. Chem. 273:1998;12893-12900.
10. Barenholz Y., Thompson T.E. Sphingomyelins in bilayers and biological membranes. Biochim. Biophys. Acta. 604:1980;129-158.
11. Barenholz Y., Roitman A., Gatt S. Enzymatic hydrolysis of sphingolipids. Hydrolysis of sphingomyelin by an enzyme from rat brain. J. Biol. Chem. 241:1966;3731-3737.
12. Basu M., Girzadas M., Dastgheib S., Baker J., Rossi F., Radin N.S., Basu S. Ceramide glycanase from rat mammary tissues: inhibition by PPMP (D-/L-) and its probable role in signal transduction. Ind. J. Biochem. Biophys. 34:1997;142-149.
13. Beaudet A.L., Manschreck A.A. Metabolism of sphingomyelin by intact cultured fibroblasts: differentiation of Niemann-Pick disease types A and B. Biochem. Biophys. Res. Commun. 105:1982;14-19.
14. Boesen de Cock J.G.R., Tepper A.D., de Vries E., van Blitterswijk W.J., Borst J. CD95 (Fas/APO-1) induces ceramide formation and apoptosis in the absence of a functional acid sphingomyelinase. J. Biol. Chem. 273:1998;7560-7565.
15. Boucher L.M., Wiegmann K., Fütterer A., Pfeffer K., Machleidt T., Schütze S., Mak T.W., Krönke M. CD28 signals through acidic sphingomyelinase. J. Exp. Med. 181:1995;2059-2068.
16. Boudker O., Futerman A.H. Detection and characterization of ceramide-1-phosphate phosphatase activity in rat liver plasma membrane. J. Biol. Chem. 268:1993;22150-22155.
17. Brady R.O., Kanfer J.N., Mock M.B., Fredrickson D.S. The metabolism of sphingomyelin. II. Evidence of an enzymatic deficiency in Niemann-Pick disease. Proc. Natl. Acad. Sci. USA. 55:1966;366-369.
18. Chatelut M., Harzer K., Christomanou H. et al. Model SV40-transformed fibroblast lines for metabolic studies of human prosaposin and acid ceramidase deficiencies. Clin. Chim. Acta. 262:1997;61-76.
19. Chatelut M., Leruth M., Harzer K., Dagan A., Marchesini S., Gatt S., Salvayre R., Courtoy P., Levade T. Natural ceramide is unable to escape the lysosome, in contrast to a fluorescent analogue. FEBS Lett. 426:1998;102-106.
20. Cifone M.G., Roncaioli P., De Maria R., Camarda G., Santoni A., Ruberti G., Testi R. Multiple pathways originate at the Fas/APO-1 (CD95) receptor: sequential involvement of phosphatidylcholine-specific phospholipase C and acidic sphingomyelinase in the propagation of the apoptotic signal. EMBO J. 14:1995;5859-5868.
21. De Maria R., Rippo M.R., Schuchman E.H., Testi R. Acidic sphingomyelinase (ASM) is necessary for Fas-induced GD3 ganglioside accumulation and efficient apoptosis of lymphoid cells. J. Exp. Med. 187:1998;897-902.
22. Desai N.N., Spiegel S. Sphingosylphosphorylcholine is a remarkably potent mitogen for a variety of cell lines. Biochem. Biophys. Res. Commun. 181:1991;361-366.
23. NTR with Trk receptors. J. Biol. Chem. 270:1995;22135-22142.
24. Ferlinz K., Hurwitz R., Vielhaber G., Suzuki K., Sandhoff K. Occurrence of two molecular forms of human acid sphingomyelinase. Biochem. J. 301:1994;855-862.
25. Fowler S. Lysosomal localization of sphingomyelinase in rat liver. Biochim. Biophys. Acta. 191:1969;481-484.
26. Gatt S., Dinur T., Kopolovic J. Niemann-Pick disease: presence of the magnesium-dependent sphingomyelinase in brain of the infantile form of the disease. J. Neurochem. 31:1978;547-550.
27. Gatt S. Magnesium-dependent sphingomyelinase. Biochem. Biophys. Res. Commun. 68:1975;235-241.
28. Graber D., Salvayre R., Levade T. Accurate differentiation of neuronopathic and nonneuronopathic forms of Niemann-Pick disease by evaluation of effective residual lysosomal sphingomyelinase activity in intact cells. J. Neurochem. 63:1994;1060-1068.
29. Grassmé H., Gulbins E., Brenner B., Ferlinz K., Sandhoff K., Harzer K., Lang F., Meyer T.F. Acidic sphingomyelinase mediates entry of N. gonorrhoeae into nonphagocytic cells. Cell. 91:1997;605-615.
30. Haimovitz-Friedman A., Cordon-Cardo C., Bayoumy S., McLoughlin M., Gallily R., Edwards C.K., Schuchman E.H., Fuks Z., Kolesnick R. Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation. J. Exp. Med. 186:1997;1831-1841.
31. Hannun Y.A. The sphingomyelin cycle and the second messenger function of ceramide. J. Biol. Chem. 269:1994;3125-3128.
32. Hannun Y.A. Functions of ceramide in coordinating cellular responses to stress. Science. 274:1996;1855-1859.
33. Herr I., Wilhelm D., Böhler T., Angel P., Debatin K.M. Activation of CD95 (Apo-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis. EMBO J. 16:1997;6200-6208.
34. Hoekstra D., Kok J.W. Trafficking of glycosphingolipids in eukaryotic cells. Sorting and recycling of lipids. Biochim. Biophys. Acta. 1113:1992;277-294.
35. Horinouchi K., Erlich S., Perl D.P., Ferlinz K., Bisgaier C.L., Sandhoff K., Desnick R.J., Stewart C.L., Schuchman E.H. Acid sphingomyelinase deficient mice: a model of types A and B Niemann-Pick disease. Nature Genet. 10:1995;288-293.
36. Hostetler K.Y., Yazaki P.J. The subcellular localization of neutral sphingomyelinase in rat liver. J. Lipid Res. 20:1979;456-463.
37. Huang C., Ma W., Ding M., Bowden G.T., Dong Z. Direct evidence for an important role of sphingomyelinase in ultra-violet-induced activation of c-Jun N-terminal kinase. J. Biol. Chem. 272:1997;27753-27757.
38. Hurwitz R., Ferlinz K., Vielhaber G., Moczall H., Sandhoff K. Processing of human acid sphingomyelinase in normal and I-cell fibroblasts. J. Biol. Chem. 269:1994;5440-5445.
39. Ito M., Kurita T., Kita K. A novel enzyme that cleaves the N-acyl linkage of ceramides in various glycosphingolipids as well as sphingomyelin to produce their lyso forms. J. Biol. Chem. 270:1995;24370-24374.
40. Jackson R.L., Morrisett J.D., Gotto A.M. Lipoprotein structure and metabolism. Physiol. Rev. 56:1976;259-316.
41. Jaffrézou J.P., Levade T., Bettaieb A., Andrieu N., Bezombes C., Maestre N., Vermeersch S., Rousse A., Laurent G. Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. EMBO J. 15:1996;2417-2424.
42. Kanfer J.N., Young O.M., Shapiro D., Brady R.O. The metabolism of sphingomyelin. Purification and properties of a sphingomyelin-cleaving enzyme from rat liver tissue. J. Biol. Chem. 241:1966;1081-1084.
43. Kolesnick R.N. Sphingomyelin and derivatives as cellular signals. Prog. Lipid Res. 30:1991;1-38.
44. Koval M., Pagano R.E. Lipid recycling between the plasma membrane and intracellular compartments: transport and metabolism of fluorescent sphingomyelin analogues in cultured fibroblasts. J. Cell Biol. 108:1989;2169-2181.
45. Koval M., Pagano R.E. Sorting of an internalized plasma membrane lipid between recycling and degradative pathways in normal and Niemann-Pick, type A fibroblasts. J. Cell Biol. 111:1990;429-442.
46. Koval M., Pagano R.E. Intracellular transport and metabolism of sphingomyelin. Biochim. Biophys. Acta. 1082:1991;113-125.
47. Kudoh T., Velkoff M.A., Wenger D.A. Uptake and metabolism of radioactively labeled sphingomyelin in cultured skin fibroblasts from controls and patients with Niemann-Pick disease and other lysosomal storage diseases. Biochim. Biophys. Acta. 754:1983;82-92.
48. Kuno K., Sukegawa K., Ishikawa Y., Orii T., Matsushima K. Acid sphingomyelinase is not essential for the IL-1 and tumor necrosis factor receptor signaling pathway leading to NF-κB activation. Int. Immunol. 6:1994;1269-1272.
49. Levade T., Gatt S. Uptake and degradation of fluorescent sphingomyelin by fibroblasts from normal individuals and a patient with Niemann-Pick disease. Biochim. Biophys. Acta. 918:1987;250-259.
50. Levade T., Salvayre R., Douste-Blazy L. Comparative hydrolysis of sphingomyelin and 2-N-(hexadecanoyl)-amino-4-nitrophenyl-phosphorylcholine by normal human brain homogenate at acid and neutral pH. J. Neurochem. 40:1983;1762-1764.
51. Levade T., Salvayre R., Douste-Blazy L. Sphingomyelinases and Niemann-Pick disease. J. Clin. Chem. Clin. Biochem. 24:1986;205-220.
52. Levade T., Salvayre R., Maret A., Douste-Blazy L. Evidence for both endogenous and exogenous sources of the sphingomyelin storage in lymphoid cell lines from patients with Niemann-Pick disease types A and B. J. Inher. Metab. Dis. 11:1988;151-157.
53. Levade T., Gatt S., Maret A., Salvayre R. Different pathways of uptake and degradation of sphingomyelin by lymphoblastoid cells and the potential participation of the neutral sphingomyelinase. J. Biol. Chem. 266:1991;13519-13529.
54. Levade T., Gatt S., Salvayre R. Uptake and degradation of several pyrene-sphingomyelins by skin fibroblasts from control subjects and patients with Niemann-Pick disease. Biochem. J. 275:1991;211-217.
55. Levade T., Vidal F., Vermeersch S., Andrieu N., Gatt S., Salvayre R. Degradation of fluorescent and radiolabelled sphingomyelins in intact cells by a non-lysosomal pathway. Biochim. Biophys. Acta. 1258:1995;277-287.
56. Levade T., Leruth M., Graber D., Moisand A., Vermeersch S., Salvayre R., Courtoy P. In situ assay of acid sphingomyelinase and ceramidase based on LDL-mediated lysosomal targeting of ceramide-labeled sphingomyelin. J. Lipid Res. 37:1996;2525-2538.
57. Linardic C.M., Hannun Y.A. Identification of a distinct pool of sphingomyelin involved in the sphingomyelin cycle. J. Biol. Chem. 269:1994;23530-23537.
58. Liu P., Anderson R.G.W. Compartmentalized production of ceramide at the cell surface. J. Biol. Chem. 270:1995;27179-27185.
59. Mazière J.C., Mora L., Routier J.D., Polonovski J. In situ degradation of sphingomyelin by cultured normal fibroblasts and fibroblasts from patients with Niemann-Pick disease type A and C. Biochem. Biophys. Res. Commun. 108:1982;1101-1106.
60. Mazière J.C., Mazière C., Mora L., Polonovski J. Impairment of exogenous sphingomyelin degradation in cultured fibroblasts from familial hypercholesterolemia. FEBS Lett. 173:1984;159-163.
61. Merrill A.H., Jones D.D. An update of the enzymology and regulation of sphingomyelin metabolism. Biochim. Biophys. Acta. 1044:1990;1-12.
62. Morimoto S., Martin B.M., Kishimoto Y., O'Brien J.S. Saposin D: a sphingomyelinase activator. Biochem. Biophys. Res. Commun. 156:1988;403-410.
63. Moser, H.W., 1995. Ceramidase deficiency: Farber lipogranulomatosis. In: Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D. (Eds.), The Metabolic and Molecular Bases of Inherited Disease, seventh ed. Mc Graw-Hill, New York, pp. 2589-2599.
64. Nilsson A. The presence of sphingomyelin- and ceramide-cleaving enzymes in the small intestinal tract. Biochim. Biophys. Acta. 176:1969;339-347.
65. Nyberg L., Duan R.D., Axelsson J., Nilsson A. Identification of an alkaline sphingomyelinase activity in human bile. Biochim. Biophys. Acta. 1300:1996;42-48.
66. 3-induced HL-60 cell differentiation. J. Biol. Chem. 269:1994;4070-4077.
67. Otterbach B., Stoffel W. Acid sphingomyelinase-deficient mice mimic the neurovisceral form of human lysosomal storage disease (Niemann-Pick disease). Cell. 81:1995;1053-1061.
68. Rao B.G., Spence M.W. Sphingomyelinase activity at pH 7.4 in human brain and a comparison to activity at pH 5.0. J. Lipid Res. 17:1976;506-515.
69. Riboni L., Viani P., Bassi R., Prinetti A., Tettamanti G. The role of sphingolipids in the process of signal transduction. Prog. Lipid Res. 36:1997;153-195.
70. Santana P., Pena L.A., Haimovitz-Friedman A., Martin S., Green D., McLoughlin M., Cordon-Cardo C., Schuchman E.H., Fuks Z., Kolesnick R. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell. 86:1996;189-199.
71. 2+-stimulated sphingomyelinase is secreted by many cell types and is a product of the acid sphingomyelinase gene. J. Biol. Chem. 271:1996;18431-18436.
72. Schissel S.L., Jiang X., Tweedie-Hardman J., Jeong T., Camejo E.H., Najib J., Rapp J.H., Williams K.J., Tabas I. Secretory sphingomyelinase, a product of the acid sphingomyelinase gene, can hydrolyze atherogenic lipoproteins at neutral pH. Implications for atherosclerotic lesion development. J. Biol. Chem. 273:1998;2738-2746.
73. Schneider P.B., Kennedy E.P. Sphingomyelinase in normal human spleens and in spleens from subjects with Niemann-Pick disease. J. Lipid Res. 8:1967;202-209.
74. Schuchman, E.H., Desnick, R.J., 1995. Niemann-Pick disease types A and B: acid sphingomyelinase deficiencies. In: Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D. (Eds.), The Metabolic and Molecular Bases of Inherited Disease , seventh ed. Mc Graw-Hill, New York, pp. 2601-2624.
75. Schütze S., Potthoff K., Machleidt T., Berkovic D., Wiegmann K., Krönke M. TNF activates NF-κB by phosphatidylcholine-specific phospholipase C-induced 'acidic' sphingomyelin breakdown. Cell. 71:1992;765-776.
76. Shinghal R., Scheller R.H., Bajjalieh S.M. Ceramide 1-phosphate phosphatase activity in brain. J. Neurochem. 61:1993;2279-2285.
77. Spence M.W., Burgess J.K. Acid and neutral sphingomyelinases of rat brain. Activity in developing brain and regional distribution in adult brain. J. Neurochem. 30:1978;917-919.
78. Spence M.W., Clarke J.T.R., Cook H.W. Pathways of sphingomyelin metabolism in cultured fibroblasts from normal and sphingomyelin lipidosis subjects. J. Biol. Chem. 258:1983;8595-8600.
79. 2+-stimulated sphingomyelinase in fetal bovine serum. J. Biol. Chem. 264:1989;5358-5363.
80. Spiegel S., Merrill A.H. Sphingolipid metabolism and cell growth regulation. FASEB J. 10:1996;1388-1397.
81. Spiegel S., Foster D., Kolesnick R.N. Signal transduction through lipid second messengers. Current Op. Cell Biol. 8:1996;159-167.
82. Stoffel B., Bauer P., Nix M., Deres K., Stoffel W. Ceramide-independent CD28 and TCR signaling but reduced IL-2 secretion in T cells of acid sphingomyelinase-deficient mice. Eur. J. Immunol. 28:1998;874-880.
83. Sutrina S.L., Chen W.W. Lysosomal involvement in cellular turnover of plasma membrane sphingomyelin. Biochim. Biophys. Acta. 793:1984;169-179.
84. 2+-dependent, neutral sphingomyelinase in nuclei of rat ascites hepatoma cells. J. Biochem. 106:1989;593-598.
85. Testi R. Sphingomyelin breakdown and cell fate. Trends Biol. Sci. 21:1996;468-471.
86. Tomiuk S., Hofmann K., Nix M., Zumbansen M., Stoffel W. Cloned mammalian neutral sphingomyelinase: functions in sphingolipid signaling? Proc. Natl. Acad. Sci. USA. 95:1998;3638-3643.
87. van Helvoort A., van't Hof W., Ritsema T., Sandra A., van Meer G. Conversion of diacylglycerol to phosphatidylcholine on the basolateral surface of epithelial (Madin-Darby canine kidney) cells. Evidence for the reverse action of sphingomyelin synthase. J. Biol. Chem. 269:1994;1763-1769.
88. Vanier M.T., Rousson R., Garcia I., Bailloud G., Juge M.C., Revol A., Louisot P. Biochemical studies in Niemann-Pick disease. III. In vivo and in vitro assays of sphingomyelin degradation in cultured skin fibroblasts and amniotic fluid cells for the diagnosis of the various forms of the disease. Clin. Genet. 27:1985;20-32.
89. Wenger D.A., Sattler M., Clark C., Wharton C. I-cell disease: activities of lysosomal enzymes toward natural and synthetic substrates. Life Sci. 19:1976;413-420.
90. Zhang P., Liu B., Jenkins G.M., Hannun Y.A., Obeid L.M. Expression of neutral sphingomyelinase identifies a distinct pool of sphingomyelin involved in apoptosis. J. Biol. Chem. 272:1997;9609-9612.
91. Zumbansen M., Stoffel W. Tumor necrosis factor α activates NF-κB in acid sphingomyelinase-deficient mouse embryonic fibroblasts. J. Biol. Chem. 272:1997;10904-10909.